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Abstract
The results of a recently published Canadian study suggest that
bronchoalveolar lavage and endotracheal aspiration are associated
with similar clinical outcomes and similar overall use of antibiotics
in critically ill patients with suspected ventilator-associated pneu-
monia (VAP). The study, however, does not provide convincing
information on the best strategy to diagnose VAP, to accurately
choose initial treatment and to exclude VAP in order to avoid
administering antibiotics to patients without bacterial infection. In
fact, this trial has several limitations or drawbacks: patients at risk
for developing VAP due to Pseudomonas aeruginosa or methicillin-
resistant Staphylococcus aureus were excluded, far from the real-
life scenario; a significant number of patients were receiving recent
antimicrobial therapy at the time of sampling, with, consequently,
difficult-to-interpret culture results; randomization of included
patients for initial treatment – meropenem plus ciprofloxacin or
meropenem alone – resulted in a high rate of inappropriate initial
empirical therapy due to the absence of customization to local
epidemiology; and the initial decision to treat and the re-evaluation
at day 3 were, in fact, based on clinical judgment and not on direct
examination and quantitative culture results. In summary, because
antimicrobial treatment was initiated in all suspected patients and
was rarely withheld in patients with negative cultures, the study
does not suggest an appropriate strategy for improving the use of
antibiotics in intensive care unit patients. Such a strategy has two
requirements: immediate administration of adequate therapy in
patients with true VAP, and avoidance of administering antibiotics
in patients without bacterial infection.
A new trial conducted by the Canadian Critical Care Trials
Group investigated the impact of different diagnostic
approaches on outcomes of patients suspected of having
ventilator-associated pneumonia (VAP) [1]. The diagnosis of
VAP has been a controversial subject for more than 15 years
[2,3]. Immediate administration of adequate antibiotic therapy
is critical to improving survival in patients with VAP. At the
same time, appropriate antimicrobial stewardship includes
not only limiting the use of inappropriate agents in patients
with VAP, but also improving our ability to diagnose and
exclude infection in the intensive care unit (ICU) setting in
order to avoid administering antibiotics to patients without
bacterial infection [4].
This recent published randomized trial [1] comparing the
quantitative culture of bronchoalveolar lavage (BAL) fluid and
the culture of endotracheal aspirate in critically ill patients
with suspected VAP adds to the information presented by
four previous trials [5-8]. The Canadian Critical Care Trials
Group found that the two diagnostic techniques were
associated with similar clinical outcomes and similar overall
use of antibiotics (Table 1). Several considerations should be
taken into account, however, to appropriately evaluate the
possible impact of diagnostic techniques on the individual
(patient morbidity and mortality) and on the collective
(emergence and dissemination of antibiotic-resistant strains)
outcomes.
First, as clearly underlined by Kollef in his related editorial [9],
the exclusion of patients previously colonized or infected with
methicillin-resistant Staphylococcus aureus or Pseudomonas
species and the exclusion of those patients having previously
received the ‘study drugs’ (that is, meropenem and/or
ciprofloxacin) resulted in a low rate of studied patients with
‘high-risk’ pathogens responsible for VAP. A proportion of less
than 12% of difficult-to-treat pathogens, such as
P. aeruginosa, Acinetobacter spp., Stenotrophomonas malto-
philia, and/or methicillin-resistant S. aureus, as compared with
more than 30% in the French study [8], diminishes the
usefulness of the results of this study in real life.
Second, 29% of patients managed using BAL had new
antibiotics initiated within 3 days before randomization,
probably after the onset of the first signs in relation to VAP,
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which is problematic when using quantitative culture tech-
niques. In this case, a negative finding or a result below the
usual threshold of 104 colony-forming units/ml could indicate
either that the patient has been successfully treated for
pneumonia and the bacteria are eradicated, or that there was
no lung infection to begin with [10]. These authors did not
give any information on how decisions regarding antibiotic
treatment were taken in this group of patients.
Third, the authors report a relatively high rate (14%) of
inappropriate initial empirical therapy in the BAL group. As
indicated above, the low frequency of high-risk, difficult-to-
treat pathogens responsible for pneumonia cannot explain
such a disappointing result, when compared with the 0.5%
rate of inappropriate initial therapy reported by Fagon and
coworkers in the invasive strategy group [8]. The most
probable explanation is that all patients included in this study
were also randomized to receive a fixed combination therapy
or monotherapy as initial treatment: meropenem plus cipro-
floxacin or meropenem alone. Several studies have clearly
established that initial antimicrobial therapy in patients with
VAP should be customized to local epidemiology at the ICU
level [11].
Fourth, even on day 6 the rate of targeted therapy was only
74.2% in the BAL arm, underlining the fact that, in many
patients managed using this diagnostic technique, early de-
escalation was not performed although clearly indicated.
Unfortunately, information on how decision algorithms were
followed in the two study arms once cultures were available
(as soon as day 2 or day 3) was not given. Obviously, the
potential benefit of using a diagnostic tool such as BAL for
safely restricting unnecessary antimicrobial therapy in such a
setting can only be obtained when decisions regarding
antibiotics are closely linked to bacteriological – both direct
examination and cultures – results [12]. In the current study,
BAL was not used for identifying patients with VAP who
needed antimicrobial therapy; this decision was essentially
left to the ICU physicians in charge of the included patients
on the basis of their clinical judgment, even when BAL culture
results were <104 colony-forming units/ml. Interestingly, the
proportion of ‘confirmed pneumonia’ was 86% in the BAL
group and 83% in the endotracheal aspirate group. In
contrast to previous recommendations concerning the use of
quantitative BAL, therefore, many patients with quantitative
culture results below the cut-off point of 104 colony-forming
units/ml continued to receive antibiotics, even after day 3.
This could entirely explain why there was a similar use of
antibiotics in the two study arms.
Finally, a major benefit of a negative BAL specimen may be to
direct attention away from the lungs as the source of fever
and, in the absence of antibiotic interference, to more readily
diagnose other potential sites of infection. Delaying diagnosis
or definitive treatment of the true site of infection may lead to
prolonged antibiotic therapy and to induction of additional
dysfunction [13,14]. In the current trial, we are left with
uncertainties regarding the numbers of extrapulmonary
infection in the two arms of the trial, as well as how long the
recommended duration of therapy in patients with VAP
should be and the how patients were managed in case of a
second episode.
In summary, even if the results of the Canadian study are
consistent with those of the three Spanish trials (Table 2) in
which antimicrobial treatment was also initiated in all
suspected patients and rarely withheld in patients with
negative cultures, our own bias is that additional studies will
be needed before one can conclude that a strategy based on
the systematic collection of distal pulmonary secretions prior
to the introduction of new antibiotics and quantitative culture
techniques is useless. In real life, the key issue is to be able to
Table 1
Outcomes and antibiotics in the Canadian Critical Care Trials Group study [1]
Endotracheal aspiration  Bronchoalveolar lavage 
(n = 374) (n = 365)
Outcomes
Mortality at day 28 (%) 18.4 18.9
Duration of mechanical ventilation (days) 8.8 (7.0–10.7) 8.9 (7.4–10.7)
Duration of intensive care unit stay (days) 12.2 (10.9–14.2) 12.3 (10.9–13.8)
Final diagnosis of ventilator-associated pneumonia (%) 82.9 86.3
Antibiotics
Adequacy of empirical treatment among patients with positive cultures (%) 89.5 89.0
Targeted therapy by day 6 (%) 74.6 74.2
Number of days alive without antibiotics 10.4 ± 7.5 10.6 ± 7.9
No differences were statistically significant.Page 3 of 3
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adhere to a de-escalation strategy, which is the only way to
curb the unnecessary use of antibiotics in the ICU. The
predominant impact of pretest opinion and the absence of
clear bacteriological-based decision algorithms in the current
study may unfortunately encourage physicians to pursue
antibiotics in most patients after 2 days, even once results of
bacterial cultures are available.
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Table 2
Results of the randomized studies of diagnostic techniques
28-day mortality (%) Antibiotic usage
Study Sample size Invasive arm Clinical arm Invasive arm Clinical arm
Sanchez-Nieto et al. [5] 51 45.8 26.7 ND ND
Ruiz et al. [6] 76 37.8 46.1 13 ± 4a 12 ± 4
Sole Violan et al. [7] 88 22.2 20.9 ND ND
Fagon et al. [8] 413 30.9 38.8 11.5 ± 9.0b 7.5 ± 7.6
Canadian Critical Care Trials Group [1] 739 18.9 18.4 10.4 ± 7.5c 10.6 ± 7.9
ND, not determined. aRuiz et al. [6] reported the total duration of antibiotic treatment; p = 0.48. bFagon et al. [8] reported antibiotic-free days;
p < 0.002. cThe Canadian Critical Care Trials Group [1] reported antibiotic-free days; p = 0.86.